← Back to Search

Other

RQC for Alzheimer's Disease

Phase 2
Waitlist Available
Led By Paul A Knepper, MD, PhD
Research Sponsored by Zaparackas and Knepper LTD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ability to take oral medication and be willing to adhere to the RQC regimen
50-90 years of age at screening
Must not have
Clinical diagnosis of any non-Alzheimer's disease (AD) type of mild cognitive impairment (MCI) or dementia
Taking pharmaceutical anti-Aβ monoclonal antibodies (i.e., Leqembi, Aduhelm)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 12 months, 24 months

Summary

This trial aims to see if a combination of oral resveratrol, quercetin, and curcumin can help prevent the buildup of amyloid-β in the retina and slow down

Who is the study for?
Adults aged 50-90 with early-stage Alzheimer's (Stage 1 or 2) are eligible for this trial. They should be able to take oral supplements and undergo eye scans using OCT. People with other serious health issues, those who can't follow the study protocol, or those allergic to the supplements' ingredients cannot participate.
What is being tested?
The trial is testing if a combination of resveratrol, quercetin, and curcumin (RQC), taken orally for two years, can prevent brain and eye changes linked to Alzheimer's. It will compare RQC's effects on cognitive function and retinal amyloid-β against curcumin alone.
What are the potential side effects?
Possible side effects may include digestive discomfort due to the supplements. Since these compounds are generally considered safe at moderate doses, severe side effects are not common but monitoring will occur for any unexpected reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take pills and will follow the treatment plan.
Select...
I am between 50 and 90 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with a type of mild cognitive impairment or dementia that is not Alzheimer's.
Select...
I am currently taking medication for Alzheimer's disease.
Select...
I have liver or kidney disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 12 months, 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 12 months, 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Retinal Amyloid-β
Secondary study objectives
Adverse Events (AEs) and Serious Adverse Events (SAEs)
Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Score
Change in Mini Mental State Examination (MMSE) Score
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Resveratrol, Quercetin, and Curcumin (RQC)Experimental Treatment1 Intervention
Resveratrol, Quercetin, and Curcumin (RQC) galactomannan formulations taken orally twice daily for 24 months.
Group II: CurcuminPlacebo Group1 Intervention
Curcumin taken orally twice daily during the 7 days preceding each study visit in order to label retinal amyloid-β.

Find a Location

Who is running the clinical trial?

Zaparackas and Knepper LTDLead Sponsor
Northwestern University Feinberg School of MedicineOTHER
40 Previous Clinical Trials
15,193 Total Patients Enrolled
Paul A Knepper, MD, PhDPrincipal InvestigatorNorthwestern University
1 Previous Clinical Trials
150 Total Patients Enrolled
~133 spots leftby Jul 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top